Opinion: STAT+: Why does the FDA want to stop improving medicines via patent ‘areas of concern’?

It’s hardly unprecedented for one federal agency to encroach on another’s turf. But the latest intra-executive-branch dustup is particularly eyebrow-raising.

This fall, acting FDA Commissioner Janet Woodcock wrote a letter to the U.S. Patent and Trademark Office to share “areas of concern” about patents issued for prescription medications.

Continue to STAT+ to read the full story…